Stay updated on Pembrolizumab After Weekly Paclitaxel Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab After Weekly Paclitaxel Clinical Trial page.

Latest updates to the Pembrolizumab After Weekly Paclitaxel Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedFallopian Tube Cancer was added to the conditions list and a new Resources section with the Genetic and Rare Diseases Information Center was added. The page footer now shows Revision: v3.4.2.SummaryDifference0.2%

- Check20 days agoChange DetectedThe page now shows a revision update from v3.4.0 to v3.4.1 with no visible changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedGlossary display was added, and metadata related to QC updates was added (Last Update Submitted that Met QC Criteria) along with Revision: v3.4.0. The older QC label variant, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing Revision: v3.3.3, which is a minor metadata update that does not affect trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter updates: added Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2. These are administrative changes unrelated to the clinical trial details.SummaryDifference0.1%

- Check92 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab After Weekly Paclitaxel Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab After Weekly Paclitaxel Clinical Trial page.